Neuren Pharmaceuticals (ASX:NEU) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Neuren requested the halt pending details regarding Neuren’s Phase 2 clinical trial of trofinetide in Rett syndrome.
The halt will remain in place until the opening of trade on Wednesday 22nd March 2017, or earlier if an announcement is made to the market.